Pancreatic Cancer Research

ResearcherSeoul National UniversityActive in the last 2 years

Hee Seung Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2825-3160; OpenAlex author ID A5100398154. Sources: OpenAlex.

Their work

Papers
47 (first author 10, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
75
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 4 papers · 2017: 6 papers · 2018: 2 papers · 2019: 3 papers · 2020: 5 papers · 2021: 8 papers · 2022: 8 papers · 2023: 4 papers · 2024: 4 papers · 2025: 2 papers

Papers 47

  1. Early response evaluation using CT and CA 19-9 in patients with pancreatic cancer of all stages undergoing first-line FOLFIRINOX treatment. Co-author DOI 10.1016/j.pan.2025.02.007↗
  2. Early prediction of liver metastasis in pancreatic cancer using routine clinical data: an externally validated machine learning model. Last author DOI 10.1186/s12885-025-15285-4↗
  3. Long-Term Outcomes of Neoadjuvant Therapy Versus Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/cam4.70363↗
  4. Uncovering the clinicopathological features of early recurrence after surgical resection of pancreatic cancer. First author DOI 10.1038/s41598-024-52909-4↗
  5. Survival predictors in patients with pancreatic cancer on liposomal irinotecan plus fluorouracil/leucovorin: a multicenter observational study. First author DOI 10.1177/17588359241279688↗
  6. Integrative analysis of spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with … Co-author DOI 10.1186/s13073-024-01287-7↗
  7. A TEAD2-Driven Endothelial-Like Program Shapes Basal-Like Differentiation and Metastasis of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2023.02.049↗
  8. Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-2045↗
  9. Difference of Risk of Pancreatic Cancer in New-Onset Diabetes and Long-standing Diabetes: A Population-based Cohort Study. Co-author DOI 10.1210/clinem/dgac728↗
  10. Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients with pancreatic cancer: a prospective stud… Co-author DOI 10.3389/fonc.2023.1206565↗
  11. A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma. Co-author DOI 10.1002/ijc.34144↗
  12. Regional lymph node metastasis detected on preoperative CT and/or FDG-PET may predict early recurrence of pancreatic adenocarcinoma after curative resection. Co-author DOI 10.1038/s41598-022-22126-y↗
  13. Retrospective Evaluation of Treatment Response in Patients with Nonmetastatic Pancreatic Cancer Using CT and CA 19-9. Co-author DOI 10.1148/radiol.212236↗
  14. Healthcare vulnerability disparities in pancreatic cancer treatment and mortality using the Korean National Sample Cohort: a retrospective cohort study. Co-author DOI 10.1186/s12885-022-10027-2↗
  15. BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients. Co-author DOI 10.3390/cancers14010236↗
  16. Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study. First author DOI 10.3390/cancers14051244↗
  17. Evaluation of the 8th Edition AJCC Staging System for the Clinical Staging of Pancreatic Cancer. Co-author DOI 10.3390/cancers14194672↗
  18. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis. First author DOI 10.5009/gnl20301↗
  19. Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy. Co-author DOI 10.1007/s00261-020-02661-w↗
  20. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2021.103218↗
  21. Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jgh.15265↗
  22. Initial experience of irreversible electroporation for locally advanced pancreatic cancer in a Korean population. Co-author DOI 10.1177/0284185120917118↗
  23. Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, p… First author DOI 10.1177/17588359211056179↗
  24. GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08898-y↗
  25. Usefulness of Smartphone Apps for Improving Nutritional Status of Pancreatic Cancer Patients: Randomized Controlled Trial. Last author DOI 10.2196/21088↗
  26. Identification of Circulating Serum miRNAs as Novel Biomarkers in Pancreatic Cancer Using a Penalized Algorithm. First author DOI 10.3390/ijms22031007↗
  27. Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer. First author DOI 10.1007/s00280-020-04051-x↗
  28. Radiographic portal or superior mesenteric vein invasion is an independent prognostic factor in non-metastatic pancreatic ductal adenocarcinoma: A missing bloc… Co-author DOI 10.1016/j.pan.2020.05.017↗
  29. Preoperative prediction of futile surgery in patients with radiologically resectable or borderline resectable pancreatic adenocarcinoma. Co-author DOI 10.1111/jgh.14837↗
  30. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. Co-author DOI 10.4251/wjgo.v12.i2.182↗
  31. Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer. First author DOI 10.5009/gnl18419↗
  32. Establishment of pancreatic cancer cell lines with endoscopic ultrasound-guided biopsy via conditionally reprogrammed cell culture. Co-author DOI 10.1002/cam4.2210↗
  33. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy. Co-author DOI 10.1080/01635581.2019.1597906↗
  34. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001319↗
  35. Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer. Co-author DOI 10.1038/s41598-018-21823-x↗
  36. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. Co-author DOI 10.4251/wjgo.v10.i11.421↗
  37. The DNA aptamer binds stemness-enriched cancer cells in pancreatic cancer. First author DOI 10.1002/jmr.2591↗
  38. A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance. Co-author DOI 10.1038/srep41615↗
  39. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A sing… Co-author DOI 10.1053/j.seminoncol.2018.01.001↗
  40. The Significance of the Prognostic Nutritional Index for All Stages of Pancreatic Cancer. Co-author DOI 10.1080/01635581.2016.1250921↗
  41. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreati… Co-author DOI 10.1097/md.0000000000005702↗
  42. Clinical characteristics of second primary pancreatic cancer. Co-author DOI 10.1371/journal.pone.0179784↗
  43. Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2. Co-author DOI 10.1016/j.dld.2015.12.006↗
  44. Statin Use and Its Impact on Survival in Pancreatic Cancer Patients. Co-author DOI 10.1097/md.0000000000003607↗
  45. Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer. First author DOI 10.3349/ymj.2016.57.5.1124↗
  46. Systemic Chemotherapy in Advanced Pancreatic Cancer. Co-author DOI 10.5009/gnl15465↗
  47. SB365, Pulsatilla saponin D suppresses proliferation and induces apoptosis of pancreatic cancer cells. Co-author DOI 10.3892/or.2013.2517↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Seungmin Bang · 40 shared papers, 2016–2025 · strength 5.10
  2. Moon Jae Chung · 34 shared papers, 2016–2025 · strength 4.00
  3. Jeong Youp Park · 33 shared papers, 2016–2025 · strength 3.88
  4. Seung Woo Park · 32 shared papers, 2016–2024 · strength 3.68
  5. Jung Hyun Jo · 25 shared papers, 2017–2025 · strength 3.47
  6. Si Young Song · 32 shared papers, 2016–2024 · strength 3.44
  7. Mi‐Suk Park · 11 shared papers, 2017–2025 · strength 1.64
  8. Seung‐seob Kim · 8 shared papers, 2020–2025 · strength 1.35
  9. Huapyong Kang · 10 shared papers, 2017–2024 · strength 1.12
  10. Jiyoung Keum · 7 shared papers, 2020–2025 · strength 1.07
  11. Ho Kyoung Hwang · 7 shared papers, 2020–2024 · strength 0.95
  12. Chang Moo Kang · 5 shared papers, 2020–2024 · strength 0.63
  13. Dawoon Jung · 5 shared papers, 2017–2023 · strength 0.60
  14. Jae Bock Chung · 6 shared papers, 2016–2025 · strength 0.59
  15. Kyung In Shin · 3 shared papers, 2024–2025 · strength 0.56
  16. Jae Hee Cho · 3 shared papers, 2022–2025 · strength 0.53
  17. Sung Ill Jang · 3 shared papers, 2022–2025 · strength 0.53
  18. Sang Hoon Lee · 5 shared papers, 2016–2024 · strength 0.46
  19. Jee Hoon Kim · 2 shared papers, 2024–2025 · strength 0.38
  20. Sunyoung Lee · 2 shared papers, 2021–2022 · strength 0.36
  21. Woo Jung Lee · 3 shared papers, 2020–2022 · strength 0.35
  22. Chan Su Park · 2 shared papers, 2023–2024 · strength 0.34
  23. In Rae Cho · 4 shared papers, 2017–2021 · strength 0.34
  24. Sung‐In Jang · 2 shared papers, 2022–2023 · strength 0.33
  25. Min Sung Yoon · 2 shared papers, 2022–2024 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.